Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares slip overall but German blue-chips hit record high

Fri, 28th Jul 2023 17:31

STOXX 600 dips 0.2% but posts weekly gains

*

Germany's DAX hits record high

*

BOJ policy tweak lifts European yields

*

Capgemini slides as Q2 growth slows

July 28 (Reuters) - European shares retreated from multi-month highs on Friday after a mixed bag of earnings and a surprise Bank of Japan policy tweak, but German blue-chips bucked the trend to close at a record high on signs of cooling inflation.

The pan-European STOXX 600 index ended 0.2% lower after closing at its highest level in nearly 1-1/2 years on Thursday when the European Central Bank hiked interest rates as expected but raised the possibility of a pause in September.

Rattling investor nerves, the BoJ made its yield curve control policy more flexible and loosened its defence of a long-term interest rate cap, in moves seen as a prelude to an eventual shift away from the massive monetary stimulus.

"We have the last of the accommodative central banks moving away from accommodative policies," said Steve Sosnick, chief strategist at Interactive Brokers.

"The fear of this BOJ move was because it can really affect hedge funds' carry trade...there was a fear that this could really spiral out from Japan yields (but) it hasn't happened."

Germany's DAX index hit an intraday record and held on to most of the gains to close 0.39% higher after data showed inflation resumed a downward trend in Europe's largest economy.

However, separate data showed the economy stagnated in the second quarter of 2023, missing forecasts for modest growth

Elsewhere, Spanish consumer prices rose by a more than anticipated 2.3% in the 12 months through July.

Despite Friday's weakness, the benchmark STOXX 600 notched up a third straight week of gains, on hopes that the Federal Reserve and the ECB are nearly done hiking interest rates.

Tech stocks and miners were among the week's top gainers, adding 3.6% and 3.4% respectively.

Hermes rose 3.9% as sales at the Birkin bag maker accelerated in the second quarter, while AstraZeneca advanced 3.3% after reporting forecast-beating profit and sales.

French drugmaker Sanofi slipped 2.9% as quarterly sales fell short of estimates, and French IT consulting group Capgemini tumbled 7.0% on a bigger-than-expected slowdown in second-quarter growth.

Austrian sensor maker AMS Osram jumped 18.5% after the company presented a strategic re-alignment of the group and reported second-quarter results in line with its expectations.

Pan-European stock and derivatives exchange Euronext climbed 7.4%, boosted by the launch of a 200-million-euro ($219.88 million) share buyback programme. (Reporting by Sruthi Shankar, Amruta Khadekar and Shristi Achar A in Bengaluru; Editing by Kirsten Donovan)

More News
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.